|
gptkbp:instanceOf
|
gptkb:drug
bisphosphonate
|
|
gptkbp:approvalYear
|
2001
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
gptkb:M05BA08
|
|
gptkbp:brand
|
gptkb:Zometa
gptkb:Reclast
|
|
gptkbp:CASNumber
|
118072-93-8
|
|
gptkbp:contraindication
|
severe renal impairment
hypocalcemia
|
|
gptkbp:discoveredBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
146 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstApprovedCountry
|
gptkb:United_States
|
|
gptkbp:form
|
solution for infusion
|
|
gptkbp:hasMolecularFormula
|
C5H10N2O7P2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
zoledronic acid
|
|
gptkbp:KEGGID
|
D08610
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits osteoclast-mediated bone resorption
|
|
gptkbp:MedlinePlusID
|
a601247
|
|
gptkbp:MeSH_ID
|
gptkb:D000077321
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:patent
|
gptkb:Novartis
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:PubChem_CID
|
CHEMBL685
61927
68740
DB00399
|
|
gptkbp:riskFactor
|
hypocalcemia
osteonecrosis of the jaw
renal toxicity
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
fever
joint pain
muscle pain
flu-like symptoms
osteonecrosis of the jaw
|
|
gptkbp:UNII
|
N8PC8044L9
|
|
gptkbp:usedFor
|
treatment of osteoporosis
treatment of hypercalcemia of malignancy
treatment of Paget's disease of bone
prevention of skeletal fractures in cancers
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Zometa
|
|
gptkbp:bfsLayer
|
5
|